

1 **Title: The estimated disease burden of COVID-19 in Japan from 2020 to 2021**

2 **Running title: Disease burden of COVID-19 in Japan, 2020-2021**

3

4 Shinya Tsuzuki, MD, MSc^{1,2,3*}; Philippe Beutels, PhD²

5 ¹ Disease Control and Prevention Center, National Center for Global Health and
6 Medicine, Tokyo, Japan

7 ² Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium

8 ³ AMR Clinical Reference Center, National Center for Global Health and Medicine,
9 Tokyo, Japan

10

11 *Corresponding author: Shinya Tsuzuki, MD, MSc

12 National Center for Global Health and Medicine

13 1-21-1 Toyama, Shinjuku-ku, Tokyo 162-8655, Japan

14 Tel: +81(0)3-3202-7181

15 Email: stsuzuki@hosp.ncgm.go.jp

16

17 **Abstract**

18 **Background:** To date, it is not fully understood to what extent COVID-19 has burdened
19 society in Japan. This study aimed to estimate the total disease burden due to COVID-
20 19 in Japan during 2020-2021.

21 **Methods:** We stratify disease burden estimates by age group and present it as absolute
22 Quality Adjusted Life Years (QALYs) lost and QALYs lost per 100,000 persons. The
23 total estimated value of QALYs lost consists of (1) QALYs lost brought by deaths due
24 to COVID-19, (2) QALYs lost brought by inpatient cases, (3) QALYs lost brought by
25 outpatient cases, and (4) QALYs lost brought by long-COVID.

26 **Findings:** QALYs lost due to COVID-19 was estimated as 286,781.7 for two years,
27 114.0 QALYs per 100,000 population per year. 71.3% of them were explained by the
28 burden derived from deaths. Probabilistic sensitivity analysis showed that the burden of
29 outpatient cases was the most sensitive factor.

30 **Interpretation:** The large part of disease burden due to COVID-19 in Japan from the
31 beginning of 2020 to the end of 2021 was derived from Wave 3, 4, and 5 and the
32 proportion of QALYs lost due to morbidity in the total burden increased gradually. The
33 estimated disease burden was smaller than that in other high-income countries. It will be
34 our future challenge to take other indirect factors into consideration.

35 **Fundings:** This research was funded by JSPS KAKENHI [Grant number 20K10546].

36 The funders had no role in study design, data collection and analysis, decision to

37 publish, or preparation of the manuscript.

38

39 **Keywords:** COVID-19; disease burden; Japan

40 **Word count:** 3,588

41 **Acknowledgment**

42 Not Applicable.

43

44 **Author contributions**

45 Shinya Tsuzuki: Conceptualization, Funding Acquisition, Data Curation, Formal

46 Analysis, Methodology, Visualization, Original Draft Preparation. Philippe Beutels:

47 Supervision, Project Administration, Review & Editing.

48

49 **Data availability**

50 The data that support the findings of this study are freely available through online.

51

52

53 **Conflict of interest**

54 ST reports payment for supervising medical articles outside this study from Gilead

55 Sciences, Inc. PB reports grants from Pfizer, GlaxoSmithKline, and the European

56 Commission IMI, unrelated to this work.

57

58 **Ethics approval**

59 This study analysed data which were publicly available. As such, the datasets used in
60 our study were de-identified and fully anonymized in advance, then therefore this this
61 study did not require ethical approval.

62

63

64

65 **Introduction**

66 Coronavirus disease 2019 (COVID-19) caused by the SARS-CoV-2 virus, has become a
67 global health threat since the beginning of 2020¹⁻³. In Japan, it was first detected in
68 early 2020⁴.

69 This emerging infectious disease became one of the most pressing concerns for
70 the Japanese general population and the Ministry of Health, Labour and Welfare
71 (MHLW) Japan in early 2020 and the Prime Minister of Japan declared the state of
72 emergency on 7th April 2020 for seven prefectures including the Tokyo metropolitan
73 area⁵⁻⁷. MHLW recommended to avoid Three Cs (Closed spaces, Crowded places, and
74 Close-contact settings) to prevent COVID-19 transmission⁸ and behaviour of the
75 general population drastically changed. The number of healthcare facility visits and the
76 consumption of antimicrobials decreased substantially after the emergence of COVID-
77 19 in Japan^{9,10}. In short, the COVID-19 pandemic changed the Japanese
78 way of life substantially.

79 To date, it is not fully understood to what extent this novel emerging disease
80 has burdened society. A quantification of the observed burden, despite the great efforts
81 that were made to minimise it, is a first step towards understanding how pandemic
82 management can be improved.

83 Compared with other high-income countries, the cumulative incidence of

84 COVID-19 cases, hospitalisations and deaths has been comparatively small in Japan, at
85 least until the end of the year 2021¹¹. For instance, the United Kingdom reported 952.6
86 cumulative hospitalizations per 100,000 population¹² and the United States reported
87 11,700.6 cumulative hospitalizations per 100,000 population at the end of 2021¹³, while
88 Japan reported 1,706.1 cumulative hospitalizations per 100,000 population in the same
89 period. As for deaths, Japan reported lower rates (14.6 deaths per 100,000 population)
90 compared with the UK and the US (218.1 and 247.8 deaths per 100,000 population,
91 respectively) and the average of the world (69.1 deaths per 100,000 population)¹⁴.

92 In order to learn from the crisis and be better prepared for future pandemics, we
93 aim to assess the burden caused by COVID-19 in more detail. We can classify the
94 disease burden directly caused by COVID-19 into four categories;

95

- 96 (i) Quality Adjusted Life Year (QALY) losses caused by fatal cases
- 97 (ii) QALY losses caused by outpatient cases
- 98 (iii) QALY losses caused by mild to severe inpatient cases
- 99 (iv) QALY losses caused by long-COVID¹⁵

100

101 Since they can be both interpreted as indicators of pandemic management, here we aim

102 to document both the cumulative and the chronological, per-wave, disease burden
103 caused by COVID-19. The COVID-19 epidemic in Japan was characterised by five
104 waves in 2020 and 2021. We adopted a previously proposed classification of waves
105 observed in Japan¹⁶, as follows (see also Figure 2):

106

107 (i) First wave (Wave 1), 01/01/2020-05/31/2020;

108 (ii) Second wave (Wave 2), 06/01/2020-10/31/2020;

109 (iii) Third wave (Wave 3), 11/01/2020-03/31/2021;

110 (iv) Fourth wave (Wave 4), 4/1/2021-6/30/2021;

111 (v) Fifth wave (Wave 5), 7/1/2021-12/31/2021

112

113 The Japanese government had implemented different non-pharmaceutical interventions
114 (NPIs) in each period and the guidelines for clinical management of COVID-19 cases
115 grew gradually, implying the characteristics of the burden in each wave are expected to
116 be different.

117 The main objective of this study is to assess the disease burden caused by
118 COVID-19 in Japan between the beginning of 2020 and the end of 2021 in order to
119 enable comparisons over time, with other diseases and with other countries.

120

121 **Methods**

122 **Settings**

123 We constructed a progression pathway model of COVID-19 infection (Figure 1), in
124 which two types of infection; symptomatic and asymptomatic, and three degrees of
125 severity were defined; outpatient cases, inpatient cases (mild), and inpatient cases
126 (severe). The definition of “severe” inpatient cases varied by prefecture because each
127 prefecture defined the severity of inpatient COVID-19 cases by its own criteria. A large
128 part of prefectures defined “severe” cases as patients admitted to an intensive care unit
129 (ICU) or patients requiring mechanical ventilation. Additionally, we assumed that any
130 type of symptomatic infection could lead to long-COVID. In line with previous
131 studies^{17,18}, we defined long-COVID patients as presenting with COVID-19 symptoms
132 for longer than four weeks from symptom onset. The final stage of each infected case
133 was “Death” or “Recovery”. We assumed that all symptomatic infections (both
134 outpatient and inpatient cases), including long-COVID episodes, and deaths contributed
135 to the disease burden, whereas asymptomatic infections did not.

136

137 (Figure 1)

138

139 We estimated the disease burden due to COVID-19 in Japan for the period
140 from the beginning of 2020 to the end of 2021 because the first case of COVID-19 in
141 Japan was detected on 15th January 2020⁴, and by the end of 2021 80.4% of the
142 population had received their primary course of COVID-19 vaccination. Additionally,
143 the less severe Omicron variant of concern (VOC), became dominant early in 2022, and
144 its clinical, detection and epidemiological characteristics were quite different from other
145 strains.

146

147 **Data sources**

148 We used open data sources for the daily number of confirmed cases and deaths¹⁹.
149 Demographic data were sourced from official statistics²⁰. Disability of each health status
150 was presented as QALYs lost per episode and defined according to values from the
151 literature^{17,21,22}. We assumed the proportion of acute symptomatic COVID-19 cases that
152 gives rise to long-COVID was 16.6% in adults and 3.9% in children^{23,24}. An overview
153 of these parameters is shown in Table 1.

154

155

156

157 **Table 1. Details of parameters included in the model**

Parameters	Value	Distribution	Reference
Disutility (QALYs lost)			
Outpatient case	0.033	Lognormal (mean = -5.187, SD = 0.034)	21
Inpatient case	0.439	Normal (mean = 0.439, SD = 0.027)	22
Long-COVID	0.129	Lognormal (mean = -4.209, SD = 2.597)	17
Proportion with long-COVID			
In adults	0.166	Binomial	23
In children (under 20)	0.039	Binomial	24

158

159

160 **Estimation of disease burden**

161 We stratify the disease burden estimates by age group and present it as absolute QALYs

162 lost^{25,26} and QALYs lost per 100,000 persons.

163

164 QALYs lost due to premature mortality were calculated as the remaining life

165 expectancy at the time of death per fatal case, i.e., the number of life years lost (LYL).

166 We used nine age groups, in accordance with available Covid-19 mortality statistics: <

167 10 years, 10-19 years, 20-29 years, 30-39 years, 40-49 years, 50-59 years, 60-69 years,

168 70-79 years, 80-89 years, and ≥ 90 years, and assumed deaths reported within a given
169 age group occurred at the mid-point of the age interval, in line with previous studies^{27,28}.

170 QALYs lost due to inpatient cases were calculated by multiplying the total
171 number of mild/severe inpatient cases with the disutility per COVID-19 inpatient case.
172 Similarly, QALYs lost due to outpatient and long-COVID cases were calculated by
173 multiplying the total number of outpatient and long-COVID cases with the respective
174 disutilities per case (see table 1).

175 The total disease burden of COVID-19 was expressed as the sum of the above,
176 i.e., the QALYs lost due to disease in inpatient cases, outpatient cases and due to
177 premature deaths.

178 Two-sided p values of < 0.05 were considered to show statistical significance.

179 All analyses were conducted by R, version 4.1.3²⁹.

180

181 **Sensitivity analysis**

182 We conducted probabilistic sensitivity analysis to acknowledge uncertainty and examine
183 the robustness of our results. We ran 1,000 simulations of the disease burden estimation
184 with different sets of parameter values derived from the defined ranges and distributions.
185 The range of each parameter, distribution, and the references we used to determine it are

186 available in Table 1. The influence of each parameter on the total disease burden was
187 evaluated by a linear regression analysis with 1,000 simulation results as an independent
188 variable and 1,000 parameter sets as dependent variables.

189

190

191 **Ethics approval**

192 All data used in this study are publicly available. As such, the datasets used in our study
193 were de-identified and fully anonymized. Therefore, this study did not require specific
194 ethical approval.

195

196

197 **Results**

198 In total, 1,728,228 COVID-19 cases were confirmed in Japan from the beginning of
199 2020 to the end of 2021. Among them, 232,495 cases were observed in 2020 and
200 1,495,733 cases in 2021. A relatively small number of cases was observed in Waves 1
201 and 2 (99,959 cases and 1,765 deaths) in Japan, and more than half of the total cases
202 between 2020 and 2021 were observed in Wave 5 (931,393 cases), although the number
203 of deaths in Wave 5 was comparatively small (3,762 deaths). Similarly, the maximum

204 number of cases requiring hospitalization in Wave 1 was 6,250, while in Wave 5 it was
205 231,596. Figure 2 shows the epidemic curve of confirmed cases and number of cases
206 requiring hospitalization from 2020 to 2021. When the life years lost were adjusted by
207 the age-specific population norm for health-related quality of life (as shown in the
208 Supplementary file), the interpretation of these results did not change.

209

210 (Figure 2)

211

212 More than a half of total cases were observed in Wave 5 (931,393 cases). The
213 Delta variant of concern (VOC) was dominant in this period^{30,31}, as it outcompeted the
214 less transmissible Alpha VOC in July 2021.

215 The number of fatal cases was 3,095 in 2020 and 14,520 in 2021. The case-
216 fatality ratio (CFR) was 0.013 in 2020 and 0.0097 in 2021, respectively. The estimated
217 average age of fatal cases was 80.2 (Wave 1 and 2), 82.3 (Wave 3), 81.5 (Wave 4), and
218 75.8 (Wave 5) years.

219

220 QALYs lost due to COVID-19 were estimated as 286,781 over two years, or an
221 average of 114.0 QALYs per 100,000 population per year. The observed disease burden

222 differed substantially between waves: from 8.5 QALYs per 100,000 population in Wave
223 1, up to 96.2 QALYs per 100,000 population in Wave 5. Figure 3 shows the evolution of
224 QALYs lost per 100,000 population in the total population and by broad age group
225 (under 40, 40-69, and over 69) over the waves. The disease burden in younger age
226 groups gradually increased during the study period with 36.4%, 47.6%, 36.6%, 45.0%
227 and 68.2% of the QALYs lost occurring in the age groups younger than 70 in Waves 1
228 through 5, respectively. When life years lost are adjusted for quality these percentages
229 become 38.7%, 50.7%, 39.6%, 48.3%, and 70.7%, respectively.

230

231 (Figure 3)

232

233 More than 70% of QALYs were lost due to premature mortality (204,437.2 out
234 of 286,781.7, 71.3%), while nearly 20% were lost due to morbidity in outpatient cases
235 (57031.5 QALYs lost, 19.9%), and only a small part of the burden came from morbidity
236 in severe cases (422.5 QALYs lost, 0.1%). Long-COVID accounts for 3.4% of the total
237 disease burden (9,791.7 QALYs lost). Figure 4 shows the breakdown of disease burden
238 attributed to each clinical status.

239

240 (Figure 4)

241

242 Probabilistic sensitivity analysis showed the disease burden directly due to
243 COVID-19 ranged between 226,883 and 512,236 (median 242,834, IQR 236,108 to
244 254,488) QALYs, or between 90.1 and 203.6 (median 96.5, IQR 93.8 to 101.1) QALYs
245 per 100,000 population. The disutility per outpatient case was the most influential
246 parameter for the estimated QALY losses due to morbidity, whereas the disutility per
247 long-COVID patient was the second most influential. Figure 5 shows the influence of
248 these and the other input parameters by their coefficient in a linear regression analysis
249 using 1,000 input parameter sets and 1,000 associated QALY estimates. Clearly,
250 accurate estimates for the disutilities per outpatient and per long-COVID patient are
251 important to estimate the burden of disease from COVID-19.

252

253 **(Figure 5)**

254

255 **Discussion**

256 To the best of our knowledge, this is the first study which estimated the disease
257 burden directly due to COVID-19 in Japan in the first two years of the pandemic. The

258 disease burden brought by this emerging infectious disease during the first two years
259 was smaller than in most other high-income countries (HICs). For instance, McDonald
260 and colleagues reported that the total disease burden per-capita in the Netherlands in
261 2020 due to COVID-19 was 1,640 Disability-adjusted life-years (DALYs) per 100,000
262 population³². This number is more than ten times higher than that of our study. Other
263 countries, e.g., Scotland and Malta, also reported similar size of burden in 2020^{33,34}.
264 Germany and Denmark reported smaller burden, however, the results were still much
265 larger than ours (368 and 520 DALYs/100,000, respectively)^{35,36}.

266 An obvious difference between previous studies and ours is that we used QALYs
267 instead of DALYs to express burden of disease. Many guidelines advocate the use of a
268 combined measure of morbidity and mortality as preferred outcome in economic
269 evaluation, and the majority of country-specific guidelines, including those for Japan,
270 prescribe the use of QALYs³⁷, although some influential generic guidelines such as the
271 IDSI³⁸ and the 2019 WHO guide for economic evaluation of vaccinations³⁹ indicate that
272 the choice between these outcome measures may depend on the analyst's preference and
273 of the specific intervention under study. QALYs were used in our study to include the
274 disease burden attributable to long-COVID based on a previous observational Japanese
275 study using the EQ-5D-3L questionnaire¹⁷. Although this choice may limit the

276 comparability with studies using DALYs as an outcome, it allows us to attain our
277 primary objective, i.e., assessing the disease burden by clinical manifestation, wave and
278 age group, and have a basis to start from to assess the QALY impact of interventions (as
279 one would for economic evaluation). Furthermore, DALYs were conceived in a very
280 similar manner as QALYs, and applied studies using both measures have reported
281 relatively small differences²⁵.

282 As for the total disease burden, this could be simply attributed to the relatively small
283 number of confirmed cases and deaths per population in Japan¹¹. Mortality of COVID-
284 19 cases was smaller in Japan than in most other HICs during the study period^{19,40-42}.
285 With regard to the number of deaths, the total number of all-cause excess deaths from
286 the beginning of 2020 to the end of 2021 was estimated at between 11,014 and 58,905,
287 while all-cause exiguous deaths in the same period was between 9,069 and 45,185⁴³.
288 Considering these numbers included the influence of diseases other than COVID-19, the
289 number of indirect deaths due to COVID-19 might not change the total burden estimates
290 substantially. One can speculate about the reasons why the COVID-19 case and death
291 toll tended to be lower in Japan than in many other HICs. Basically, people who
292 presented fever or any symptoms suspicious of COVID-19 were required to visit one of
293 the designated medical facilities and physicians who diagnosed COVID-19 had to report

294 all COVID-19 cases they diagnosed, implying the potential risk of underestimating the
295 number of cases was low. The cumulative number of COVID-19 cases in Japan
296 increased most steeply after the emergence of the Omicron VOC, and the proportion of
297 the Japanese population with non-vaccine induced immunity against COVID-19
298 remained low, even in 2021⁴⁴.

299 Considering the breakdown of QALYs lost, the part of the burden attributable to
300 fatal cases was smaller than that in previous studies. Although only 71.3% of QALYs
301 lost was attributed to fatal cases in our study, more than 90% of the total burden was
302 attributed to LYL in previous studies in other countries³²⁻³⁶. It may be partly explained
303 by some studies not including the burden of long-COVID. Furthermore, we have used a
304 simplified approach by counting each lost life year as one, implying that each of these
305 life years was assumed to be lived in perfect health. We also made estimates accounting
306 for a quality adjustment in the life years gained, and as expected, this leads to lower
307 estimates of the QALYs lost due to premature mortality.

308 The probabilistic sensitivity analysis acknowledges parametric uncertainty and
309 indicates a relatively wide range for the total disease burden. This might be attributed to
310 uncertainty in the estimation of the burden of outpatient cases and long-COVID because
311 we defined the range of disease burden caused by these two statuses according to

312 empirical data in our previous studies^{17,21}, then small sample sizes affected their
313 uncertainty. Additionally, it would also be due to the fact that there is no single
314 established definition of long-COVID. Tsuzuki et al defined long-COVID as four weeks
315 or longer duration of symptoms after diagnosis of COVID-19¹⁷, however, WHO defines
316 post COVID-19 condition as the status “usually 3 months from the onset of COVID-19
317 with symptoms and that last for at least 2 months and cannot be explained by an
318 alternative diagnosis”⁴⁵. With changing definitions, the proportion of symptomatic cases
319 incurring long-COVID varies significantly. In addition, disutility of each long-COVID
320 case varies substantially by study⁴⁶⁻⁴⁸ which will bring further uncertainty.

321 There are several limitations in this study, similar to the previous studies. First, our
322 results did not consider how many cases were unreported. As described above, all
323 diagnosed COVID-19 cases including asymptomatic ones had to be reported in Japan,
324 nevertheless some level of underreporting seems inevitable. For instance, McKenzie and
325 colleagues insisted that there might be 1.77 times higher number of cases than reported
326 during the same period (from the beginning of 2020 to the end of 2021)⁴⁹. It is difficult
327 for us to estimate the precise cumulative incidence of COVID-19 because we have very
328 little evidence on the seroprevalence of SARS-CoV-2 in Japan^{44,49}. However, most of
329 such unreported cases were expected to be “asymptomatic” because they had to be

330 reported if they presented any suspicious symptoms. Since our objective is to assess the
331 disease burden directly attributable due to COVID-19, we can ignore such cases,
332 although they may have given rise to anxiety, especially in 2020, and have an impact on
333 mental wellbeing in both the infected person and their direct contacts in and outside the
334 household.

335 Second, we did not take the burden to the healthcare systems into consideration.
336 Japanese government decided to admit all the patients diagnosed with COVID-19
337 regardless of its severity in the early phase of the pandemic⁵. As a result, a large number
338 of tertiary hospitals could not offer normal healthcare due to high burden of the
339 management of COVID-19 cases. This would have brought additional burden to society
340 as previous studies reported^{50,51}. Nevertheless, we believe that this additional burden to
341 the healthcare system did not contribute to increase the total disease burden, because
342 excess mortality attributable to the causes other than COVID-19 was smaller than
343 before during the study period⁴³, and no large catch-up effect due to postponed care has
344 been detected in mortality statistics to date.

345 Third, we could not consider the impact of non-pharmaceutical interventions (NPIs).
346 The Japanese government had implemented a “state of emergency” declaration as a kind
347 of recommendation to avoid social contact like capital lockdown in other countries⁵².

348 Such interventions might contribute to decrease the number of COVID-19 cases in
349 exchange for the economic burden. We have scarce evidence about both the economic
350 aspects of these non-pharmaceutical countermeasures so far and a counterfactual
351 scenario about the burden of disease and the economic impact in case we had not
352 implemented such NPIs. Although it seems clear that the total disease burden due to
353 COVID-19 in Japan was relatively smaller than in most other HICs, the impact of the
354 indirect effects of NPIs on the overall disease burden remains a topic on research, as it
355 is in many other countries.

356 Fourth, we did not distinguish between primary and secondary infections in
357 unvaccinated persons and breakthrough infections in vaccinated persons. The cases
358 reported in 2021, included breakthrough infections, but we lacked the information to
359 specify these cases. Al-Aly et al. showed that the risk of death and post-acute sequelae
360 were higher in unvaccinated cases than breakthrough infections⁵³, and the total burden
361 might become slightly smaller if we consider the impact of breakthrough infection.
362 Nevertheless, the number of breakthrough infection can be considered smaller than the
363 normal ones, then its impact also should be a small one.

364 Fifth, in line with all other studies known to us, we exclude other indirect aspects of
365 the disease burden such as that caused by isolation, imposed on patients' family

366 members, and so forth, because the number of isolated persons and the number of
367 patients' household members are not well documented. Although our previous studies
368 had estimated the per-patient impact of these aspects^{21,54}, future work will attempt to
369 combine these results with the estimated number of isolated people and household
370 members of infected cases as part of a more general assessment of the indirect burden.

371

372 **Conclusions**

373 Most of the disease burden due to COVID-19 in Japan from the beginning of 2020 to
374 the end of 2021 was incurred in 2021 during waves 3, 4, and 5. The proportion of the
375 total burden due to non-fatal disease increased gradually and this was probably due to
376 the lower mortality by COVID-19 in the latter half of the study period, especially in the
377 elderly. It also shows that younger people contributed more to the disease burden as
378 SARS-CoV-2 circulated more in the general population from 2021 onwards. The
379 estimated disease burden in Japan was smaller than in most other HICs and this can be
380 attributed to the small number of confirmed cases in Japan. Future research may further
381 explore the underlying reasons for the lower cumulative incidence of COVID-19 cases
382 in Japan, while taking contextual factors into consideration.

383

385

386

References

387 1 Guan W, Ni Z, Hu Y, *et al.* Clinical Characteristics of Coronavirus Disease
388 2019 in China. *N Engl J Med* 2020; **382**: 1708–20.

389 2 Huang C, Wang Y, Li X, *et al.* Clinical features of patients infected with 2019
390 novel coronavirus in Wuhan, China. *The Lancet* 2020; **395**: 497–506.

391 3 Chen N, Zhou M, Dong X, *et al.* Epidemiological and clinical characteristics of
392 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive
393 study. *The Lancet* 2020; **395**: 507–13.

394 4 Ministry of Health, Labour and Welfare. Current status of the novel
395 coronavirus infection and the response of the MHLW.
396 https://www.mhlw.go.jp/stf/newpage_09290.html (accessed June 1, 2022).

397 5 Ministry of Health, Labour and Welfare. Information list for local authorities
398 and healthcare facilities: COVID-19. 2020.
399 https://www.mhlw.go.jp/stf/seisakunitsuite/newpage_00024.html (accessed Aug 17,
400 2021).

401 6 Matsunaga N, Hayakawa K, Terada M, *et al.* Clinical epidemiology of
402 hospitalized patients with COVID-19 in Japan: Report of the COVID-19 REGISTRY
403 JAPAN. *Clin Infect Dis* 2020; published online Sept. DOI:10.1093/cid/ciaa1470.

404 7 Inoue H. Japanese strategy to COVID-19: How does it work? *Global Health &*
405 *Medicine* 2020; **2**: 131–2.

406 8 Ministry of Health, Labour and Welfare. Information on health and medical
407 consultation. [https://www.mhlw.go.jp/stf/covid-19/kenkou-](https://www.mhlw.go.jp/stf/covid-19/kenkou-iryousoudan_00006.html)
408 [iryousoudan_00006.html](https://www.mhlw.go.jp/stf/covid-19/kenkou-iryousoudan_00006.html) (accessed Feb 23, 2022).

409 9 Yamaguchi S, Okada A, Sunaga S, *et al.* Impact of COVID-19 pandemic on
410 healthcare service use for non-COVID-19 patients in Japan: retrospective
411 cohort study. *BMJ Open* 2022; **12**: e060390.

412 10 Ono A, Koizumi R, Tsuzuki S, *et al.* Antimicrobial Use Fell Substantially in

- 413 Japan in 2020—The COVID-19 Pandemic May Have Played a Role. *International*
414 *Journal of Infectious Diseases* 2022. DOI:10.1016/j.ijid.2022.03.019.
- 415 11 Coronavirus (COVID-19) Cases - Our World in Data.
416 <https://ourworldindata.org/covid-cases> (accessed Feb 24, 2022).
- 417 12 Healthcare in the UK | Coronavirus in the UK.
418 <https://coronavirus.data.gov.uk/details/healthcare> (accessed Dec 3, 2022).
- 419 13 United States - COVID-19 Overview - Johns Hopkins. Johns Hopkins Coronavirus
420 Resource Center. <https://coronavirus.jhu.edu/region/united-states> (accessed
421 Dec 3, 2022).
- 422 14 Idogawa M, Tange S, Nakase H, Tokino T. Interactive Web-based Graphs of
423 Coronavirus Disease 2019 Cases and Deaths per Population by Country. *Clinical*
424 *Infectious Diseases* 2020; **71**: 902-3.
- 425 15 del Rio C, Collins LF, Malani P. Long-term Health Consequences of COVID-19.
426 *JAMA* 2020; published online Oct 5. DOI:10.1001/jama.2020.19719.
- 427 16 Hayakawa K, Asai Y, Matsunaga N, *et al.* Evaluation of the representativeness
428 of data in the COVID-19 Registry Japan during the first six waves of the
429 epidemic. *Global Health & Medicine* 2022. DOI:10.35772/ghm.2022.01033.
- 430 17 Tsuzuki S, Miyazato Y, Terada M, Morioka S, Ohmagari N, Beutels P. Impact of
431 long-COVID on health-related quality of life in Japanese COVID-19 patients.
432 *Health and Quality of Life Outcomes* 2022; **20**: 125.
- 433 18 Miyazato Y, Morioka S, Tsuzuki S, *et al.* Prolonged and Late-Onset Symptoms of
434 Coronavirus Disease 2019. *Open Forum Infect Dis* 2020; **7**: ofaa507.
- 435 19 Ministry of Health, Labour and Welfare. Visualizing the data: information on
436 COVID-19 infections.
437 <https://covid19.mhlw.go.jp/extensions/public/en/index.html> (accessed Feb 24,
438 2022).
- 439 20 National Institute of Population and Social Security Research. Population
440 Statistics. 2020.
441 <http://www.ipss.go.jp/syoushika/tohkei/Popular/Popular2014.asp?chap=5&title1=%>

- 442 87X%81D%8E%80%96S%81E%8E%F5%96%BD (accessed Dec 20, 2020).
- 443 21 Tsuzuki S, Ohmagari N, Beutels P. The burden of isolation to the individual: a
444 comparison between isolation for COVID-19 and for other influenza-like
445 illnesses in Japan. *Epidemiology and Infection* 2022; **150**: e5-undefined.
- 446 22 Glick HA, Miyazaki T, Hirano K, *et al.* One-Year Quality of Life Post-Pneumonia
447 Diagnosis in Japanese Adults. *Clinical Infectious Diseases* 2021; **73**: 283–90.
- 448 23 Thompson EJ, Williams DM, Walker AJ, *et al.* Long COVID burden and risk factors
449 in 10 UK longitudinal studies and electronic health records. *Nature*
450 *Communications* 2022; **13**. DOI:10.1038/s41467-022-30836-0.
- 451 24 Wulf Hanson S, Abbafati C, Aerts JG, *et al.* Estimated Global Proportions of
452 Individuals With Persistent Fatigue, Cognitive, and Respiratory Symptom
453 Clusters Following Symptomatic COVID-19 in 2020 and 2021. *JAMA* 2022.
454 DOI:10.1001/jama.2022.18931.
- 455 25 Augustovski F, Colantonio LD, Galante J, *et al.* Measuring the Benefits of
456 Healthcare: DALYs and QALYs – Does the Choice of Measure Matter? A Case Study
457 of Two Preventive Interventions. *Int J Health Policy Manag* 2017; **7**: 120–36.
- 458 26 Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW. Methods for the
459 Economic Evaluation of Health Care Programmes, 4th edn. Oxford: Oxford
460 University Press, 2015.
- 461 27 Tsuzuki S, Baguelin M, Pebody R, van Leeuwen E. Modelling the optimal target
462 age group for seasonal influenza vaccination in Japan. *Vaccine* 2020; **38**: 752–
463 62.
- 464 28 Tsuzuki S, Schwehm M, Eichner M. Simulation studies to assess the long-term
465 effects of Japan’s change from trivalent to quadrivalent influenza
466 vaccination. *Vaccine* 2018; **36**: 624–30.
- 467 29 R Core Team. R: A Language and Environment for Statistical Computing. 2018.
- 468 30 Shoji K, Akiyama T, Tsuzuki S, *et al.* Clinical characteristics of COVID-19 in
469 hospitalized children during the Omicron variant predominant period. *J Infect*
470 *Chemother* 2022; **28**: 1531–5.

- 471 31 Shoji K, Akiyama T, Tsuzuki S, *et al.* Comparison of the clinical
472 characteristics and outcomes of COVID-19 in children before and after the
473 emergence of Delta variant of concern in Japan. *J Infect Chemother* 2022; **28**:
474 591-4.
- 475 32 McDonald SA, Lagerweij GR, De Boer P, *et al.* The estimated disease burden of
476 acute COVID-19 in the Netherlands in 2020, in disability-adjusted life-years.
477 *European Journal of Epidemiology* 2022. DOI:10.1007/s10654-022-00895-0.
- 478 33 Wyper GMA, Fletcher E, Grant I, *et al.* Measuring disability-adjusted life
479 years (DALYs) due to COVID-19 in Scotland, 2020. *Archives of Public Health*
480 2022; **80**. DOI:10.1186/s13690-022-00862-x.
- 481 34 Cuschieri S, Calleja N, Devleeschauwer B, Wyper GMA. Estimating the direct
482 Covid-19 disability-adjusted life years impact on the Malta population for the
483 first full year. *BMC Public Health* 2021; **21**. DOI:10.1186/s12889-021-11893-4.
- 484 35 Rommel A, von der Lippe E, Plag D, *et al.* The COVID-19 Disease Burden in
485 Germany in 2020. *Dtsch Arztebl International* 2021; **118**: 145-51.
- 486 36 Pires SM, Redondo HG, Espenhain L, *et al.* Disability adjusted life years
487 associated with COVID-19 in Denmark in the first year of the pandemic. *BMC*
488 *Public Health* 2022; **22**. DOI:10.1186/s12889-022-13694-9.
- 489 37 Zhao Y, Feng H, Qu J, Luo X, Ma W, Tian J. A systematic review of
490 pharmaco-economic guidelines. *Journal of Medical Economics* 2018; **21**: 85-96.
- 491 38 Health Technology Assessment Toolkit. iDSI. 2017; published online Sept 7.
492 <https://www.idsihealth.org/htatoolkit/> (accessed Dec 8, 2022).
- 493 39 World Health Organization. WHO guide for standardization of economic
494 evaluations of immunization programmes, 2nd ed.
495 [https://www.who.int/publications-detail-redirect/who-guide-for-](https://www.who.int/publications-detail-redirect/who-guide-for-standardization-of-economic-evaluations-of-immunization-programmes-2nd-ed)
496 [standardization-of-economic-evaluations-of-immunization-programmes-2nd-ed](https://www.who.int/publications-detail-redirect/who-guide-for-standardization-of-economic-evaluations-of-immunization-programmes-2nd-ed)
497 (accessed Dec 8, 2022).
- 498 40 Eurosurveillance | Estimates of mortality attributable to COVID-19: a
499 statistical model for monitoring COVID-19 and seasonal influenza, Denmark,

- 500 spring 2020. [https://www.eurosurveillance.org/content/10.2807/1560-](https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.8.2001646)
501 7917.ES.2021.26.8.2001646 (accessed Feb 26, 2021).
- 502 41 Lipsitch M. Estimating case fatality rates of COVID-19. *The Lancet Infectious*
503 *Diseases* 2020; **20**: 775.
- 504 42 Pastor-Barriuso R, Pérez-Gómez B, Hernán MA, *et al.* Infection fatality risk
505 for SARS-CoV-2 in community dwelling population of Spain: nationwide
506 seroepidemiological study. *BMJ* 2020; **371**: m4509.
- 507 43 Kawashima T, Nomura S, Tanoue Y, *et al.* Excess All-Cause Deaths during
508 Coronavirus Disease Pandemic, Japan, January–May 2020 – Volume 27, Number 3–
509 March 2021 – Emerging Infectious Diseases journal – CDC.
510 DOI:10.3201/eid2703.203925.
- 511 44 Sugiyama A, Okada F, Abe K, *et al.* A longitudinal study of anti-SARS-CoV-2
512 antibody seroprevalence in a random sample of the general population in
513 Hiroshima in 2020. *Environmental Health and Preventive Medicine* 2022; **27**: 30–
514 30.
- 515 45 World Health Organization. A clinical case definition of post COVID-19
516 condition by a Delphi consensus, 6 October 2021. 2021; published online Oct 6.
517 [https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Post_COVID-](https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1)
518 19_condition-Clinical_case_definition-2021.1 (accessed Sept 19, 2022).
- 519 46 Sandmann FG, Tessier E, Lacy J, *et al.* Long-Term Health-Related Quality of
520 Life in Non-Hospitalized Coronavirus Disease 2019 (COVID-19) Cases With
521 Confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
522 Infection in England: Longitudinal Analysis and Cross-Sectional Comparison W.
523 *Clinical Infectious Diseases* 2022. DOI:10.1093/cid/ciac151.
- 524 47 Malik P, Patel K, Pinto C, *et al.* Post-acute COVID-19 syndrome (PCS) and
525 health-related quality of life (HRQoL)–A systematic review and meta-analysis.
526 *J Med Virol* 2022; **94**: 253–62.
- 527 48 Malinowska A, Muchlado M, Ślizień Z, *et al.* Post-COVID-19 Syndrome and Decrease
528 in Health-Related Quality of Life in Kidney Transplant Recipients after SARS-
529 COV-2 Infection–A Cohort Longitudinal Study from the North of Poland. *J Clin*
530 *Med* 2021; **10**: 5205.

531 49 McKenzie L, Shoukat A, Wong KO, *et al.* Inferring the true number of SARS-CoV-2
532 infections in Japan. *Journal of Infection and Chemotherapy* 2022.
533 DOI:10.1016/j.jiac.2022.08.002.

534 50 Verelst F, Kuylen E, Beutels P. Indications for healthcare surge capacity in
535 European countries facing an exponential increase in coronavirus disease
536 (COVID-19) cases, March 2020. *Eurosurveillance* 2020; **25**: 2000323.

537 51 McCabe R, Kont MD, Schmit N, *et al.* Modelling intensive care unit capacity
538 under different epidemiological scenarios of the COVID-19 pandemic in three
539 Western European countries. *International Journal of Epidemiology* 2021;
540 published online April. DOI:10.1093/ije/dyab034.

541 52 Machida M, Wada K. Public health responses to COVID-19 in Japan. *Global Health*
542 *& Medicine* 2022; **4**: 78-82.

543 53 Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection.
544 *Nat Med* 2022; **28**: 1461-7.

545 54 Tsuzuki S, Yoshihara K. The characteristics of influenza-like illness
546 management in Japan. *BMC Public Health* 2020; **20**: 568.

547

548

549 **Figure legends**

550 **Figure 1. Progression pathway diagram of COVID-19 infection**

551

552 **Figure 2. Daily number of confirmed COVID-19 cases and hospitalisations**

553 Wave 1; 01/01/2020-05/31/2020, Wave 2; 06/01/2020-10/31/2020, Wave 3; 11/01/2020-
554 03/31/2021, Wave 4; 4/1/2021-6/30/2021, Wave 5; 7/1/2021-12/31/2021

555 Bars represent the daily number of confirmed cases. The black line represents the
556 number of cases requiring hospitalization. Vertical lines represent the delimitation of
557 five epidemic waves.

558

559 **Figure 3. Comparison of QALYs lost per 100,000 population in each epidemic wave**

560 Wave 1; 01/01/2020-05/31/2020, Wave 2; 06/01/2020-10/31/2020, Wave 3; 11/01/2020-
561 03/31/2021, Wave 4; 4/1/2021-6/30/2021, Wave 5; 7/1/2021-12/31/2021

562 Light grey bars represent QALYs lost due to morbidity and dark grey bars represent
563 QALYs lost due to mortality.

564 QALYs; Quality-adjusted life years

565 Panel a: Disease burden in total population

566 Panel b: Disease burden in population under 40

567 Panel c: Disease burden in population between age 40 and 69

568 Panel d: Disease burden in population 70 and over

569

570 **Figure 4. Breakdown of disease burden by clinical manifestation of COVID-19**

571 QALYs; Quality-adjusted life years

572 *Count without quality adjustment (i.e., assuming life years lost due to premature mortality

573 would have been lived in perfect health).

574

575 **Figure 5. Linear regression coefficient of each parameter included in the probabilistic**

576 sensitivity analysis

577 X axis represents coefficient value of each parameter.

578









